Trial Profile
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 May 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2012 Planned end date changed from 1 Jan 2012 to 1 Nov 2010 as reported by ClinicalTrials.gov.